Quantum Biopharma (QNTM) Research & Development (2020 - 2026)
Quantum Biopharma (QNTM) posted Research & Development of $626092.0 for Q1 2026, up 789.28% sequentially from $70404.0 in Q4 2025, and down 62.02% YoY from $1.6 million in Q1 2025.
Quantum Biopharma (QNTM) Research & Development (2020 - 2026) Analysis & Trends
Quantum Biopharma has reported Research & Development for 7 years, with the latest figure at $626092.0 in Q1 2026.
- Quarterly Research & Development fell 62.02% year-over-year to $626092.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.7 million (down 49.56% YoY) and the FY2025 annual result came in at $2.8 million, down 54.58% from the prior year.
- Research & Development improved to $626092.0 in Q1 2026 per QNTM's latest filing, from $70404.0 in the prior quarter.
- Over five years, Research & Development peaked at $2.3 million in Q1 2023 and troughed at $32985.0 in Q3 2023.
- A 5-year average of $719517.2 and a median of $587644.5 in 2025 frame the typical range for Research & Development.
- The widest YoY moves for Research & Development: up 2158.0% in 2024, down 93.07% in 2024.
- Over 5 years, Research & Development stood at $937052.0 in 2022, then plunged by 96.48% to $32985.0 in 2023, then jumped by 385.86% to $160260.0 in 2024, then slumped by 56.07% to $70404.0 in 2025, then jumped by 789.28% to $626092.0 in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $626092.0, $70404.0, and $495223.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Quantum Biopharma | 15.53 Mn | 11.89 Mn | - | 387,428.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 387,428.00 |
| Mar 31, 2026 | 626,092.00 |
| Dec 31, 2025 | 70,404.00 |
| Sep 30, 2025 | 495,223.00 |
| Jun 30, 2025 | 549,197.00 |
| Mar 31, 2025 | 1.65 Mn |
| Dec 31, 2024 | 160,260.00 |
| Sep 30, 2024 | 744,802.00 |
| Jun 30, 2024 | 897,986.00 |
| Mar 31, 2024 | 160,260.00 |
| Sep 30, 2023 | 32,985.00 |
| Mar 31, 2023 | 2.31 Mn |
| Mar 31, 2022 | 937,052.00 |
| Jun 30, 2021 | 3.61 Mn |
| Sep 30, 2020 | 3.50 Mn |
| Jun 30, 2020 | 1.13 Mn |
| Mar 31, 2020 | 226,299.20 |